India's affordable generic medicine scheme, Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP), achieved sales of INR1,236 crore ($162m) in the fiscal year 2022-23, growing 38% YoY. The scheme exceeded its target, which was revised upwards from INR775 crore to INR1,200 crore by the government. The jump in sales was attributed to initiatives such as increasing the number of retail outlets, publicising the scheme and ensuring adequate medicine supplies. The government aims to increase the number of stores to 10,000 in FY24. The scheme also helps reduce Indian out-of-pocket expenses on medicine and has strict quality control measures.
